Forecast Next Dividend Date: Tuesday 10 September 2019
Days remaining until next forecast dividend: 76
This is only a forecast. Forecast ex-dividend dates are taken from company's website or by using previous ex-dividend dates as a guide. Please confirm ex-dividend date with your broker.
Dividend Star Rating for VERIS LIMITED(VRS)
Fundamental Data for VERIS LIMITED(VRS)Sector: Commercial & Professional Services Price: $0.05 (delayed) Year High: $0.25 Year Low: $0.05 Market Capitalisation: $0.021 billion Net Tangible Assets: $0.03 billion Earnings per Share: 0.03 cents Price Earnings Ratio: 0 Forecast Earnings Growth (5 years): 0% per annum Dividend Cover: 0
Dividend Payment History for VERIS LIMITED(VRS)
|Ex-Dividend Date||Books Close Date||Date Payable||Amount||Franking||Franking Credit||Gross Dividend||Cum Div Price||Gross Yield||RoI|
- Care should be taken interpreting this chart as all dividend payments for final year may not have been paid.
- The financial year that the dividend is allocated depends on the payment date of the dividend, not the ex-dividend date.
- Dividend history has not been adjusted for any capital reconstructions which may have effected dividend entitlement per share.
Dividend News Articles for VERIS LIMITED(VRS)
|Here are 4 fast growing ASX stocks to buy from leading microcap fund - The Capital Club|
Here are 4 fast growing ASX stocks to buy from leading microcap fund The Capital Club
The Perennial Value Microcap Opportunities Trust has gained 42 per cent over the past 12 months, easily out-performing the 20 per cent rise in its benchmark ...
|3 companies that could mover higher in 2018 - Motley Fool Australia|
3 companies that could mover higher in 2018 Motley Fool Australia
These three share shares saw solid gains on Tuesday. Here's why…
|My Concerns Around Veris Limited (ASX:VRS) - Simply Wall St|
My Concerns Around Veris Limited (ASX:VRS) Simply Wall St
Veris Limited (ASX:VRS) is a company I've been following for a while, and my main concern is around the sustainability of the business going forward.
|Is There An Opportunity With Bank of Queensland Limited’s (ASX:BOQ) Mispricing? - Simply Wall St|
Is There An Opportunity With Bank of Queensland Limited’s (ASX:BOQ) Mispricing? Simply Wall St
Pricing BOQ, a financial stock, can be difficult since these banks have cash flows that are affected by regulations that are not imposed upon other sectors.
|Veris" acquisition of Elton Consulting drives shares to 12 month high - Proactive Investors Australia|
Veris" acquisition of Elton Consulting drives shares to 12 month high Proactive Investors Australia
Veris Ltd (ASX:VRS) has completed the acquisition of Elton Consulting Group, an initiative that has seen its shares increase more than 20% in March.
|Australia's infrastructure boom is coming - Patrick Poke - Livewire Markets|
Australia's infrastructure boom is coming - Patrick Poke Livewire Markets
As the housing construction boom comes to an end, the obvious question for investors is 'where next?' One potential opportunity lies in transport infrastructure ...
|Wires Tagged "ASX:ELS" - Livewire Markets|
Wires Tagged "ASX:ELS" Livewire Markets
Veris Limited (VRS: ASX announced another acquisition in its continuing strategy to rollup firms in the surveying and urban/regional planning business.
|Wires Tagged "ASX:TTT" - Livewire Markets|
Wires Tagged "ASX:TTT" Livewire Markets
In Melbourne this week TTT will host the launch of the world's largest and fasted 3D metal printer (Wed/Thur), built using the proceeds of its $0.20 IPO back in ...
|Director Trades: Who's making $$ buying and selling their own stock? - Stockhead|
Director Trades: Who's making $$ buying and selling their own stock? Stockhead
Here's our weekly look at which ASX small cap directors are buying or selling their own stock (week of Sep 10):. There were nine multi-millon dollar deals in ...
|How Did GlaxoSmithKline plc’s (LON:GSK) 64.55% ROE Fare Against The Industry? - Simply Wall St|
How Did GlaxoSmithKline plc’s (LON:GSK) 64.55% ROE Fare Against The Industry? Simply Wall St
With an ROE of 64.55%, GlaxoSmithKline plc (LSE:GSK) outpaced its own industry which delivered a less exciting 9.57% over the past year. But what is more ...